Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Generally in good health~* Body mass index (BMI) of ≥ 18.0 and ≤ 30.0 kg/m2 at Screening, with minimum weight of 60 kg. (No BMI upper limit for mild AD and amnestic MCI subjects)~* Male subjects and their partners must be willing to comply with the contraceptive requirements of the study. Only female subjects of non-childbearing potential are eligible for participation.~* \[Young subjects\] Male subjects must be aged 18 to 45 years (inclusive) at the time of Screening.~* \[Healthy elder subjects only\] Male and female subjects must be aged 60 to 85 years at the time of screening~* \[Amnestic MCI and Alzheimer's Subjects\] 9. Patients with Alzheimer's disease, with confirmed diagnosis of amnestic mild cognitive impairment, Alzheimer's disease (mild, mild-to-moderate, or moderate), or mixed dementia with Alzheimer's and vascular components (mild, mild-to-moderate, or moderate).~  1. Either newly diagnosed treatment naïve patients, OR,~ 2. Patients who are currently on standard Alzheimer's Disease treatment may be considered for participation if they are not tolerating treatment and/or they are willing and clinically able to tolerate a discontinuation, 14 days for dose titration + 5x half-lives for washout, or 4 weeks (whichever is longer) prior to randomization. For these patients, the screening window will be allowed for up to 90 days prior to randomization to evaluate discontinuation of symptomatic treatment for Alzheimer's disease.~EXCLUSION CRITERIA:~* Any medical condition that requires chronic medication use.~* History of drug and/or alcohol abuse within 12 months prior to Screening.~* History of having taken another investigational drug within 30 days prior to Admission (Day -1).~* Donation of blood or plasma within 30 days prior to dosing.~* Major surgery within 90 days prior to Admission (Day -1) or anticipated surgery during the study.~* Smokers~* \[Healthy elderly subjects\] Reported changes in cognition and reported history of declines in everyday life in the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- NDX-1017 (Type: EXPERIMENTAL): NDX-1017 will be administered via subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).